Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IRD NASDAQ:MREO NASDAQ:SCPH NASDAQ:TLSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRDOpus Genetics$1.20+1.7%$1.06$0.65▼$1.75$70.40M0.01217,902 shs308,832 shsMREOMereo BioPharma Group$1.74+1.8%$2.20$1.47▼$5.02$276.66M0.471.77 million shs940,964 shsSCPHscPharmaceuticals$4.60-7.1%$4.54$1.94▼$6.28$263.83M0.4382,220 shs230,052 shsTLSATiziana Life Sciences$1.97-1.5%$1.76$0.63▼$2.60$230.19M-0.57546,253 shs361,629 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRDOpus Genetics+1.69%+12.15%+7.14%+17.65%+119,999,900.00%MREOMereo BioPharma Group+1.75%+13.73%-0.57%-22.32%-55.95%SCPHscPharmaceuticals-7.07%-0.65%+1.55%+42.86%-3.97%TLSATiziana Life Sciences-1.50%-10.45%+31.33%+44.85%+80.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIRDOpus Genetics1.8686 of 5 stars3.50.00.00.02.40.00.6MREOMereo BioPharma Group2.0952 of 5 stars3.61.00.00.03.11.70.0SCPHscPharmaceuticals4.4954 of 5 stars3.55.00.04.22.41.70.6TLSATiziana Life Sciences0.6488 of 5 stars0.03.00.00.02.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIRDOpus Genetics 3.00Buy$7.33511.11% UpsideMREOMereo BioPharma Group 3.20Buy$7.20313.79% UpsideSCPHscPharmaceuticals 3.00Buy$14.00204.35% UpsideTLSATiziana Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IRD, MREO, TLSA, and SCPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$7.00 ➝ $5.006/27/2025IRDOpus GeneticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIRDOpus Genetics$15.42M4.64N/AN/A$0.29 per share4.14MREOMereo BioPharma Group$500K553.32N/AN/A$0.34 per share5.12SCPHscPharmaceuticals$49.97M4.91N/AN/A($0.40) per share-11.50TLSATiziana Life SciencesN/AN/AN/AN/A$0.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIRDOpus Genetics-$57.53M-$1.92N/AN/AN/A-377.89%-384.33%-148.90%N/AMREOMereo BioPharma Group-$43.25M-$0.07N/AN/AN/AN/A-80.00%-66.94%N/ASCPHscPharmaceuticals-$85.15M-$1.81N/AN/AN/A-183.55%-1,647.86%-71.76%N/ATLSATiziana Life Sciences-$11.86MN/A0.00∞N/AN/AN/AN/A10/13/2025 (Estimated)Latest IRD, MREO, TLSA, and SCPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025IRDOpus Genetics-$0.25-$0.12+$0.13-$0.12$4.27 million$2.88 million8/12/2025Q2 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$7.80 million$0.50 million8/7/2025Q2 2025SCPHscPharmaceuticals-$0.30-$0.34-$0.04-$0.34$15.41 million$16.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIRDOpus GeneticsN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIRDOpus Genetics0.061.901.98MREOMereo BioPharma GroupN/A8.138.92SCPHscPharmaceuticals3.863.853.14TLSATiziana Life SciencesN/A1.021.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIRDOpus Genetics14.97%MREOMereo BioPharma Group62.83%SCPHscPharmaceuticals89.52%TLSATiziana Life SciencesN/AInsider OwnershipCompanyInsider OwnershipIRDOpus Genetics6.60%MREOMereo BioPharma Group5.50%SCPHscPharmaceuticals4.78%TLSATiziana Life Sciences39.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIRDOpus Genetics1459.66 million55.72 millionN/AMREOMereo BioPharma Group40159.00 million150.26 millionOptionableSCPHscPharmaceuticals3053.30 million50.75 millionOptionableTLSATiziana Life Sciences8116.85 million70.32 millionOptionableIRD, MREO, TLSA, and SCPH HeadlinesRecent News About These CompaniesTiziana Life Sciences doses first MSA patient in new trial – ICYMIAugust 15 at 4:36 PM | proactiveinvestors.comTiziana Life Sciences Initiates Phase 2a Trial for MSA with Intranasal ForalumabAugust 14 at 2:10 PM | msn.comTiziana Life doses first patient in Phase 2a trial of intranasal foralumabAugust 14 at 2:10 PM | msn.comTiziana Life Sciences doses first patient in Phase 2a MSA trialAugust 14 at 9:44 AM | proactiveinvestors.comTiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System AtrophyAugust 14 at 8:30 AM | globenewswire.comTiziana Life Sciences Phase 2a multiple system atrophy study green-lit by FDAAugust 11, 2025 | proactiveinvestors.comFDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System AtrophyAugust 11, 2025 | globenewswire.comDauntless Investment Group LLC Buys Shares of 1,739,574 Tiziana Life Sciences Ltd (NASDAQ:TLSA)July 29, 2025 | marketbeat.comTiziana Life Sciences reports encouraging results from nasal Alzheimer's treatmentJuly 21, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's PatientJuly 21, 2025 | globenewswire.comTiziana Life Sciences Ltd (TLSA) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comTiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis TargetingJune 13, 2025 | seekingalpha.comTiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosingJune 13, 2025 | proactiveinvestors.comTiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis CenterJune 13, 2025 | globenewswire.comTiziana Life Sciences to Present at the Bio International ConventionJune 13, 2025 | globenewswire.comTiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s DiseaseMay 23, 2025 | finance.yahoo.comTiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's DiseaseMay 23, 2025 | globenewswire.comJournal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's DiseaseMay 15, 2025 | finance.yahoo.comTiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study showsMay 15, 2025 | proactiveinvestors.comTiziana Life Sciences reports purchase of shares by chairmanMay 12, 2025 | msn.comTiziana Life Sciences Announces Purchase of Shares by ChairmanMay 12, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIRD, MREO, TLSA, and SCPH Company DescriptionsOpus Genetics NASDAQ:IRD$1.20 +0.02 (+1.69%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.20 0.00 (0.00%) As of 08/15/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.Mereo BioPharma Group NASDAQ:MREO$1.74 +0.03 (+1.75%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.74 0.00 (0.00%) As of 08/15/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.scPharmaceuticals NASDAQ:SCPH$4.60 -0.35 (-7.07%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$4.84 +0.24 (+5.30%) As of 08/15/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.Tiziana Life Sciences NASDAQ:TLSA$1.97 -0.03 (-1.50%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.98 +0.01 (+0.25%) As of 08/15/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore The Real Reason Ford Stock Is Rallying—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access